Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | PRKACG | P22612 | 1/20 | 0.40 |
| ▸ | PRKACB | P22694 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6423442 | 0.94 | SRC (0.39) | SRCPRKACAPRKACGPRKACBPTGS2 | |
| SCHEMBL6424777 | 0.92 | PTGS2 (0.46) | PTGS2PTGS1ABCB1AKR1C3AKR1C2 | |
| SCHEMBL6425498 | 0.92 | PTGS2 (0.40) | SRCPTGS2PTGS1ABCB1AKR1C3 | |
| SCHEMBL6424339 | 0.92 | SRC (0.41) | SRCPRKACAPRKACGPRKACBPTGS2 | |
| SCHEMBL6425595 | 0.90 | AKR1C3 (0.42) | SRCPTGS2PTGS1ABCB1AKR1C3 | |
| SCHEMBL6424835 | 0.88 | SRC (0.40) | SRCPRKACAPRKACGPRKACBPTGS2 | |
| SCHEMBL6424991 | 0.88 | PTGS2 (0.54) | PTGS2PTGS1ABCB1PLA2G2AAKR1C3 | |
| SCHEMBL6424811 | 0.88 | SRC (0.42) | SRCPRKACAPRKACGPRKACBPTGS2 | |
| SCHEMBL6425338 | 0.86 | PTGS2 (0.45) | PTGS2PTGS1ABCB1AKR1C3AKR1C2 | |
| SCHEMBL6423836 | 0.86 | PTGS2 (0.39) | PTGS2PTGS1ABCB1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643961-A4 | COX-2 AND FAAH INHIBITORS | MICROBIA INC (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1643961-A2 | COX-2 AND FAAH INHIBITORS | Microbia, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
| WO-2005002525-A2 | COX-2 AND FAAH INHIBITORS | MICROBIA, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | SRC 3467/4885PRKACA 1966/4885PRKACG 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.